Characterizing Treatment Patterns and Healthcare Use in Patients and Subgroups with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Real-World Study
Approximately one-third of the patients switched to a new treatment within 2 years after starting treatment, which could be partly due to limited efficacy of therapies in LOT1. The decrease in treatment duration after LOT1 may suggest limited utility of subsequent therapies. Frequent treatment changes and increased healthcare encounters in this subgroup highlight significant unmet needs in CIDP.
Authors
- Miguel Alonso‐Alonso (ORCID: https://orcid.org/0000-0003-3372-9933)
- Omar Saeed (ORCID: https://orcid.org/0000-0002-3600-3591)
- Alex Seluzhytsky
- Nazem Atassi (ORCID: https://orcid.org/0000-0002-1856-2330)
- Flavio Dormont (ORCID: https://orcid.org/0000-0001-7309-1853)
- Hans‐Peter Hartung (ORCID: https://orcid.org/0000-0002-0614-6989)
- Richard A. Lewis (ORCID: https://orcid.org/0000-0002-1140-4575)
- Ekaterina Smolkina
- M. Núñez (ORCID: https://orcid.org/0000-0003-4393-1510)
- M.H. Nguyen (ORCID: https://orcid.org/0000-0003-1650-1953)
- Mati Lopez‐Grancha
Institutions
- Cedars-Sinai Medical Center (US)
- The University of Sydney (AU)
- Sanofi (France) (FR)
- Sanofi (Netherlands) (NL)
- Sanofi (United States) (US)
- Sanofi (United Kingdom) (GB)
- Daiichi Sankyo (United States) (US)
- Heinrich Heine University Düsseldorf (DE)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1007/s40120-025-00862-3
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Myasthenia Gravis Foundation of America
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Celgene
- CSL Behring
- TG Therapeutics
- GBS/CIDP Foundation International
- BioCryst
- Argenx
- Grifols
- Daiichi Sankyo Europe